Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|KX2-391||KX-01|Tirbanibulin||SRC Inhibitor 29||Tirbanibulin (KX2-391) is a peptidomimetic dual inhibitor of Src and pretubulin, which inhibits SRC in a non-ATP-competitive manner, resulting in tumor growth inhibition and metastasis prevention (PMID: 22784709, PMID: 31628188).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||prostate cancer||not applicable||KX2-391||Phase II||Actionable||In a Phase II trial, KX2-391 at tested dose did not demonstrate anti-tumor effects in patients with castration-resistant prostate cancer, resulted in 8% progression free survival (PFS) at 24 weeks and median PFS of 18.6 weeks, but had modest effects on bone turnover markers (PMID: 23314737).||23314737|
|PTEN G129R||ovarian mucinous neoplasm||decreased response||KX2-391||Preclinical||Actionable||In a preclincal study, mucinous ovarian carcinoma cell lines over-expressing PTEN G129R were less sensitive to KX2-391 induced growth inhibition in culture and tumor suppression in xenograft models (PMID: 24100628).||24100628|
|PTEN loss||ovarian mucinous neoplasm||decreased response||KX2-391||Preclinical||Actionable||In a preclincal study, mucinous ovarian carcinoma cell lines harboring PTEN loss were less sensitive to KX2-391 induced growth inhibition in culture and tumor suppression in xenograft models (PMID: 24100628).||24100628|
|PTEN wild-type||ovarian mucinous neoplasm||sensitive||KX2-391||Preclinical||Actionable||In a preclinical study, KX2-391 inhibited survival of PTEN wild-type mucinous ovarian carcinoma cell lines in culture, and reduced tumor growth in xenograft models (PMID: 24100628).||24100628|
|Unknown unknown||Advanced Solid Tumor||not applicable||KX2-391||Phase I||Actionable||In a Phase I trial, KX2-391 demonstrated safety and preliminary efficacy, resulted in stable disease for more than 4 months in 25% (11/44) of patients with advanced solid tumors (PMID: 23361621).||23361621|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|